WHEN YOU CHOOSE RIABNI®

AMGEN HELPS YOU TAKE ON MANY ASPECTS OF PATIENT SUPPORT

Riabni® is the only rituximab biosimilar that provides the Amgen level of support to your patients and practice

Riabni® is the only rituximab biosimilar that provides the Amgen level of support to your patients and practice

RIABNI® is FDA approved for all Rituxan® oncology indications1,2

  • Non-Hodgkin's lymphoma (NHL)
    • - Follicular lymphoma (FL)
    • - Previously untreated large B-cell lymphoma
    • - Non-progressing (stable disease)
  • Previously untreated chronic lymphocytic leukemia (CLL)
  • FDA = Food and Drug Administration.

RIABNI™
(rituximab-arrx) has an
established Q-Code:

Q5123
RIABNI RIABNI

RIABNI™ has reached pass-through status